KuDOS   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Cambridge United Kingdom (1997)
Status: Acquired by AstraZeneca (2005)

Organization Overview

First Clinical Trial
2007
NCT00516802
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

KuDOS/AstraZeneca | KuDOS Pharmaceutical Ltd | KuDOS Pharmaceuticals Limited | KuDOS Pharmaceuticals Ltd | KuDOS Pharmaceuticals, Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

olaparib (lynparza) (7 trials)

Drugs in Phase 1 Trials (3)

bevacizumab (avastin) (1 trial)

dacarbazine (dtic-dome) (1 trial)

topotecan (hycamtin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4